Biocompatible 3D Printing Materials: A Procurement Buying Guide

Buying biocompatible material for a 3D printer is a materials-qualification decision, not a filament-color choice. Most desktop and industrial 3D printing materials — standard PLA, ABS, PETG, general-purpose photopolymer resins — are not biocompatible in any regulatory sense, and using them for anything that will contact tissue, blood, or mucous membranes, even briefly, is a real risk and, for a commercial or clinical device, a regulatory non-starter. A genuinely biocompatible 3D printing material is one with documented test data, against a recognized standard, for the specific type and duration of body contact the finished part will have.

This guide covers what “biocompatible” actually requires under ISO 10993, how FDA treats biocompatibility for additively manufactured devices, the main categories of biocompatible print materials in commercial use — resins, thermoplastics, metal powders, and bioresorbable and bioprinting materials — and what documentation to require from a supplier before you specify a material for a medical, dental, or tissue-engineering application.

What “biocompatible” means for a procurement decision

Biocompatibility is not a single pass/fail property of a material; it is an evaluation of whether a specific finished part, made from a specific material, produces an unacceptable biological response given how and how long it will contact the body. The governing framework is ISO 10993-1, Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process, which organizes testing around two variables rather than a fixed checklist:

• Nature of body contact — surface-contacting (intact skin, mucosal membrane, breached or compromised surface), external communicating (blood path, tissue/bone/dentin), or implant (tissue/bone, blood).
• Duration of contact — limited (≤24 hours), prolonged (24 hours–30 days), or permanent (>30 days).

A resin cleared for limited mucosal contact under a 24-hour exposure is not automatically suitable for a permanent implant, even if it is marketed generically as “biocompatible.” When evaluating a 3D printing material, the first procurement question is not “is this material biocompatible” but “what contact type and duration does the supplier’s biocompatibility data actually cover, and does that match the intended use of my part.” CASRAI’s guide to FDA’s biocompatibility guidance and the ISO 10993 series covers this risk-based framework in more depth.

Post-processing changes this evaluation. Uncured resin, support-structure residue, and print artifacts such as layer-line surface roughness or trapped powder can all affect biocompatibility even when the base material has qualifying test data — a resin’s ISO 10993 report typically applies to fully cured, properly washed parts, not to a print straight off the build plate. Supplier documentation should specify the post-processing steps (wash time and solvent, UV or thermal post-cure parameters, sterilization compatibility) that the biocompatibility data assumes.

FDA and biocompatible 3D printing materials

There is no such thing as a blanket “FDA-approved biocompatible material” that a manufacturer can use in any device without further testing. FDA does not pre-approve raw materials in isolation; it reviews and clears or approves specific finished devices, and biocompatibility data is one part of that device-level submission (a 510(k), De Novo request, PMA, IDE, or HDE). A resin or filament supplier can hold ISO 10993 or USP Class VI test reports for its material, and that data materially supports a device biocompatibility case, but a device maker still has to demonstrate that the finished, processed, sterilized part meets the biological evaluation endpoints appropriate to its actual clinical contact — the material’s test data is an input to that case, not a substitute for it.

For additive manufacturing specifically, FDA’s guidance Technical Considerations for Additive Manufactured Medical Devices (issued December 2017) lays out AM-specific concerns that sit alongside standard ISO 10993 testing: powder or resin residue trapped in internal lattice or channel geometries, the effect of build orientation and post-processing on surface finish and cleanability, and the need to re-evaluate biocompatibility when a print parameter, geometry, or post-processing step changes materially from what was originally tested. Under the FD&C Act’s recognized-consensus-standards mechanism (21 U.S.C. § 360d), FDA formally recognizes specific editions of ISO 10993 parts and related standards — see CASRAI’s FDA recognized consensus standards entry — and a sponsor can file a Declaration of Conformity against a recognized standard edition or justify a deviation.

Practically, this means a procurement evaluation should treat a supplier’s ISO 10993 or USP Class VI documentation as necessary but not sufficient: confirm the test reports cover your device’s actual contact type and duration, and confirm the supplier’s recommended print, wash, cure, and (if applicable) sterilization parameters are the ones the test data was generated against.

Categories of biocompatible 3D printing materials

Biocompatible print materials fall into a small number of process-linked categories. Each has a different testing basis, a different typical contact-duration ceiling, and different procurement documentation to demand.

Biocompatible resin for 3D printing medical devices

Photopolymer resins for stereolithography (SLA), digital light processing (DLP), and masked SLA (MSLA) printers are the most common route to biocompatible parts for dental appliances, surgical guides, anatomical models, and short-term skin- or mucosa-contacting devices. Several manufacturers offer dedicated medical-grade resin lines with published USP Class VI and ISO 10993 (cytotoxicity, sensitization, irritation, and in some cases longer-duration) test reports for specific contact classes — for example, Formlabs’ BioMed resin line and Stratasys’ MED-series photopolymers are both marketed with this kind of documentation, cited here as examples of what a qualifying commercial resin line looks like on paper, not as a recommendation over any competing product. When evaluating a biocompatible resin, procurement should confirm:

• Which specific ISO 10993 test reports the supplier can provide (cytotoxicity per 10993-5, sensitization and irritation per 10993-10 are the minimum baseline for surface contact; longer-duration or implant use requires additional endpoints).
• The maximum contact duration and contact type the data supports — many medical-grade resins are validated only for limited (≤24-hour) or short-term mucosal contact, not permanent implantation.
• Whether the biocompatibility claim applies to the resin as printed by any operator, or only when printed and post-cured on the specific validated printer/parameter combination the manufacturer tested.
• Autoclave or other sterilization compatibility, if the finished part needs to be sterilized before use.

Biocompatible thermoplastics for FDM/FFF

Fused deposition modeling (FDM/FFF) has a narrower set of biocompatible options than resin printing, because most filament formulations are optimized for mechanical or aesthetic properties rather than biological safety. Medical-grade thermoplastics used for FDM — certain ULTEM (polyetherimide) and PEEK formulations, and select ABS-M30i-class materials — are typically sold with ISO 10993 and, for implant-grade PEEK, longer-duration biocompatibility data supporting their use in surgical guides, cranial and spinal implant components, and anatomical models. As with resins, the biocompatibility claim is tied to a specific validated print and post-processing parameter set, not the raw pellet chemistry alone.

Biocompatible metal powders for implant-grade parts

For permanent structural implants — cranial plates, spinal cages, orthopedic components, patient-specific anatomical hardware — laser powder bed fusion using implant-grade titanium alloy (typically Ti-6Al-4V ELI, the lower-interstitial grade specified by ASTM F3001) or cobalt-chromium alloy powder is the established route, and several 3D-printed titanium and PEEK implants have received FDA 510(k) clearance for specific indications. Metal powder procurement for implant use adds materials-standard and quality-system requirements on top of biocompatibility data; CASRAI’s metal powder buying guide covers alloy specification, particle size distribution, and supplier certificate-of-analysis requirements in detail, and a medical-device metal powder supplier should also hold quality certification appropriate to medical-device supply chains, typically ISO 13485.

Bioresorbable 3D printing materials

Bioresorbable (also called bioabsorbable) materials are designed to degrade in the body over a defined period, ideally as the surrounding tissue heals or regenerates, so a second removal procedure is not required. The material classes most commonly used in bioresorbable 3D printing are:

• Polylactic acid (PLA) and other poly(alpha-hydroxy acid) polymers — hydrolytically degrade into lactic acid, which the body metabolizes; degradation rate depends on crystallinity, molecular weight, and part geometry.
• Polycaprolactone (PCL) — a slower-degrading polyester with a lower melting point than PLA, widely used in tissue-scaffold research for its printability and mechanical compliance.
• Poly(lactic-co-glycolic acid) (PLGA) — a copolymer whose degradation rate can be tuned by adjusting the lactide-to-glycolide ratio, long used in resorbable sutures and fixation devices and increasingly explored as a print feedstock.
• Calcium phosphate ceramics (hydroxyapatite, tricalcium phosphate) — osteoconductive materials often combined with a polymer binder for 3D-printed bone-void-filling scaffolds.

Bioresorbable material selection is a degradation-rate matching problem as much as a biocompatibility one: the material should resorb on a timescale compatible with the tissue’s healing or regrowth rate, and procurement or R&D evaluation needs degradation-rate data (typically from in vitro hydrolytic degradation studies) alongside standard ISO 10993 biocompatibility endpoints, since a bioresorbable material’s degradation products, not just the parent polymer, also have to be evaluated for biological safety under ISO 10993-13 (identification and quantification of degradation products for polymers).

3D printing materials for tissue scaffolds and bioprinting

Tissue-engineering scaffolds and bioprinted constructs sit at the research-intensive end of biocompatible 3D printing. Two broad approaches are in use: printing a solid, porous scaffold from a bioresorbable polymer or ceramic (the materials above) that cells populate after implantation or in culture, and direct bioprinting, which extrudes or deposits a cell-laden bioink — typically a hydrogel such as alginate, gelatin methacryloyl (GelMA), collagen, or fibrin — to build a construct with cells already embedded in it. Key procurement- and evaluation-relevant considerations for scaffold materials include:

• Porosity and pore interconnectivity, which govern cell infiltration, nutrient diffusion, and vascularization, not just mechanical strength.
• Degradation rate versus tissue regrowth rate, the same matching problem covered above for bioresorbable materials generally.
• Sterility and endotoxin control for any material or bioink that will contact cells or tissue in culture or in vivo, which is a distinct requirement from bulk-material biocompatibility.

It is worth being direct about where this field actually stands: most tissue-scaffold and bioprinting applications remain research, preclinical, or investigational-device work rather than commercially cleared products, while a narrower set of solid, non-living 3D-printed implants — cranial plates, spinal cages, patient-specific anatomical models — has achieved FDA clearance for specific indications using the more established biocompatible-metal and biocompatible-polymer routes described above. A procurement or lab-management decision should reflect that distinction rather than treating “bioprinting” and “FDA-cleared 3D-printed implant” as the same maturity level.

What documentation to require from a materials supplier

Before specifying a material for any device, part, or scaffold that will contact tissue, blood, or mucous membranes, confirm you can obtain each of the following from the supplier, not just a marketing datasheet:

• Lot-specific or formulation-specific ISO 10993 test reports (not a summary claim) identifying the exact sub-tests performed (10993-5 cytotoxicity, 10993-10 sensitization/irritation, and any additional endpoints for longer contact durations) and the contact type/duration each covers.
• USP Class VI certification where applicable, and confirmation of which USP <88> biological reactivity classes were tested.
• The validated print, post-cure, wash, and (if relevant) sterilization parameters the biocompatibility data was generated under — and whether deviating from them invalidates the claim.
• Quality-system certification appropriate to medical-device supply chains — ISO 13485 at minimum for any material intended for a regulated device, consistent with FDA’s Quality Management System Regulation, which incorporates ISO 13485:2016 by reference.
• A current safety data sheet and, for resins, cured-vs-uncured hazard information, since uncured photopolymer resin is a skin sensitizer regardless of the cured part’s biocompatibility rating.
• Lot traceability, so a specific print can be tied back to a specific resin or powder lot if a biocompatibility or quality question arises later.

A material that cannot produce this documentation on request — regardless of how it is marketed — should not be treated as qualified for tissue-, blood-, or mucosa-contacting use. This applies equally whether the material is purchased directly from the manufacturer or through a laboratory or medical-device distributor; the documentation obligation travels with the material, not the sales channel.

Frequently asked questions

What makes a 3D printing material biocompatible?

A material is biocompatible for a given use when it has documented test data, under ISO 10993 (and often USP Class VI), showing it does not produce an unacceptable biological response for the specific contact type (surface, external communicating, or implant) and duration (limited, prolonged, or permanent) the finished part will actually have — not a general marketing claim of “biocompatible” with no specified contact class.

Is there an FDA-approved list of biocompatible 3D printing materials?

No. FDA clears or approves finished devices, not raw materials in isolation. A material supplier’s ISO 10993 or USP Class VI test data supports a device’s biocompatibility case but does not itself constitute FDA approval; the device maker still has to demonstrate the finished, processed part meets the appropriate biological evaluation endpoints as part of its own submission.

What is a bioresorbable 3D printing material?

A bioresorbable (bioabsorbable) material is designed to degrade in the body over a defined period as tissue heals, avoiding a second removal procedure. Common bioresorbable print materials include PLA, PCL, and PLGA polymers and calcium phosphate ceramics; selection depends on matching the material’s degradation rate to the target tissue’s healing timeline and evaluating the degradation products, not just the parent material, for biological safety.

Can standard PLA or resin be used for medical devices?

Not for tissue-, blood-, or mucosa-contacting use. Standard, general-purpose PLA filament and general-purpose photopolymer resins are not tested or documented against ISO 10993 or USP Class VI and should not be assumed biocompatible; only dedicated medical-grade material lines with published, contact-class-specific test data should be specified for those applications.

Do 3D printing materials for tissue scaffolds need different testing than implant materials?

They need the same ISO 10993 biological-evaluation framework, applied to a different problem. Scaffold and bioprinting materials add porosity, degradation-rate matching, and sterility/endotoxin considerations specific to supporting living cells, on top of the standard biocompatibility endpoints solid implant materials are evaluated against.